Neurol. praxi. 2016;17(2):113-116 | DOI: 10.36290/neu.2016.023

Treatment of neuropathic pain

MUDr. Marek Hakl, Ph.D.
Oddělení léčby bolesti FN Brno

Neuropathic pain is one of the most difficult-to-treat pain conditions. Numerous common analgesics are not effective in treating it. Drugs from the groups of anticonvulsants, antidepressants, opioids with an increased affinity to neuropathic pain, and, recently, new topical dosage forms have been at the forefront of treatment. The occurrence of neuropathic pain increases exponentially with patient age; at the same time, however, tolerance of patients to antineuropathic treatment decreases. A major benefit in treating neuropathic pain has been the development of uniform EFNS guidelines based on which national guidelines are subsequently developed. The most common forms of neuropathic pain include polyneuropathy, trigeminal neuralgia, postherpetic neuralgia or central neurogenic pain.

Keywords: neuropathic pain, anticonvulsants, opioids, capsaicin, guidelines

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hakl M. Treatment of neuropathic pain. Neurol. praxi. 2016;17(2):113-116. doi: 10.36290/neu.2016.023.
Download citation

References

  1. Bouhassira D, Lanteri-Minet M, Attal N, Laureát B, Touboul C. Prevalence of chronic pain with neuropathic characteristic in the general population. Pain 2008, 136: 380-387. Go to original source... Go to PubMed...
  2. Attal N, Cruccu G, Baron R, Haanpaa M, Hanson P, Jensen T, Numikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. European Journal of Neurology 2009; 8: 1010-1018. Go to original source...
  3. Attal N, Cruccu G, Haanpiiii M, Haanpa M, Hanssona P, Jensena TS, Nurmikkoa T. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathicpain. EurJ Neuro 2006: 13: 1153-1169 (class I SR). Go to original source... Go to PubMed...
  4. Bednařík J, Ambler Z, Opavský J, Keller O, Rokyta R, Mazanec R, Lejčko J, Kozák J, Suchý M, Pátá M, Kožený P. Klinický standard pro farmakoterapii neuropatické bolesti. Cesk Slov Neurol 2012;75/108 (1): 93-101.
  5. Scadding JW, Koltzenburg M. Painful peripheral neuropathies. In: McMahon, Koltzenburg M: Wall and Melzack's Textbook of Pain. Elsevier, London 2006. Go to original source...
  6. Kadiroglu AK, Sit O, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME. The effect of venlafaxine HCI on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22: 241-245. Go to original source... Go to PubMed...
  7. Wiffen P, McQuay H, Edwards J, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev 2005; 20: CD005452 (class I SR). Go to original source... Go to PubMed...
  8. Katz J, Finnerup B, Dworkin RH. Clinical outcome in neuropathic pain: relationship to study characteristics. Neurology 2008; 28: 263-272 (class 1 SR). Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.